According to PTC Therapeutics 's latest financial reports the company's total liabilities are NZ$4.68 Billion. A companyโs total liabilities is the sum of all current and non-current debts and obligations.
Year | Total liabilities | Change |
---|---|---|
2024-12-31 | NZ$4.97 B | 15.8% |
2023-12-31 | NZ$4.29 B | 32.75% |
2022-12-31 | NZ$3.23 B | 14.03% |
2021-12-31 | NZ$2.83 B | 18.51% |
2020-12-31 | NZ$2.39 B | 56.52% |
2019-12-31 | NZ$1.52 B | 33.42% |
2018-12-31 | NZ$1.14 B | 245.92% |
2017-12-31 | NZ$0.33 B | 53.19% |
2016-12-31 | NZ$0.21 B | 6.24% |
2015-12-31 | NZ$0.20 B | 358.81% |
2014-12-31 | NZ$44.35 M | 137.28% |
2013-12-31 | NZ$18.69 M | -52.34% |
2012-12-31 | NZ$39.22 M | -89.17% |
2011-12-31 | NZ$0.36 B |
Company | Total liabilities | differencediff. | Country |
---|---|---|---|
![]() Vertex Pharmaceuticals VRTX | NZ$10.52 B | 124.70% | ๐บ๐ธ USA |
![]() Sarepta Therapeutics
SRPT | NZ$3.82 B | -18.25% | ๐บ๐ธ USA |
![]() Fate Therapeutics
FATE | NZ$0.18 B | -96.12% | ๐บ๐ธ USA |
![]() Avidity Biosciences RNA | NZ$0.21 B | -95.41% | ๐บ๐ธ USA |
![]() Xencor XNCR | NZ$0.43 B | -90.68% | ๐บ๐ธ USA |
![]() Novartis NVS | NZ$101.37 B | 2,064.23% | ๐จ๐ญ Switzerland |